REFERENCES
- Southam C. M., Ehrlich J. Effects of extracts of Western red-cedar hardwood on certain wood-decaying fungi in culture. Phytopathology 1943; 33: 517–524, [CSA]
- Christiani D. C., Zhou W. Hormesis: The new approach in risk assessment?. Hum Exp. Toxicol 2002; 21: 399–408, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Axelrod D., Burns K., Davis D., von Larebeke N. “Hormesis”—An inappropriate extrapolation from the specific to the universal. Int. J. Occup. Environ. Health 2004; 10: 335–339, [PUBMED], [INFOTRIEVE], [CSA]
- Crump K. Evaluating the evidence for hormesis: A statistical perspective. Crit. Rev. Toxicol 2001; 31: 669–679, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Olson H. M., Kadyszewski E., Beierschmitt W. Hormesis—A pharmaceutical industry perspective. Crit. Rev. Toxicol 2001; 31: 659–661, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kon S. H. Underestimation of chronic toxicities of food additives and chemicals: The bias of a phantom rule. Med. Hypoth. 1978; 4: 324–339, [CROSSREF], [CSA]
- Calabrese E. Hormesis: A revolution in toxicology, risk assessment and medicine. EMBO Rep. 2004; 5: S37–S40, (special issue)[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Reddel R. R., Sutherland R. L. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: A possible model for tamoxifen tumour flare. Eur. J. Cancer Clin. Oncol. 1984; 20: 1419–1424, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Plotkin D., Lechner J. J., Jung W. E., Rosen P. J. Tamoxifen flare in advanced breast cancer. J. Am. Med. Assoc. 1978; 240: 2644–2646, [CROSSREF], [CSA]
- Legha S. S., Powell K., Buzdar A U., Blumenschein G. R. Tamoxifen-induced hypercalcemia in breast cancer. Cancer 1981; 47: 2803–2806, [PUBMED], [INFOTRIEVE], [CSA]
- Legault-Poisson S., Jolivet J., Poisson R., Beretta-Piccoli M., Band P. R. Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat. Rep. 1979; 63: 1839–1841, [PUBMED], [INFOTRIEVE], [CSA]
- Belani C. P., Pearl P., Whitley N. O., Aisner J. Tamoxifen withdrawal response. Report of a case. Arch. Intern. Med. 1989; 149: 449–450, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lippert C., Seeger H., Meuck A. O. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci. 2003; 10: 877–883, [CROSSREF], [CSA]
- Lamb C., Simian M., Molinolo A., Pazos P., Lanari C. Regulation of cell growth of a progestin-dependent murine mammary carcinoma in vitro: Progesterone receptor involvement in serum or growth factor-induced cell proliferation. J. Steroid. Biochem. Mol. Biol 1999; 70: 133–142, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–1059, [CROSSREF], [CSA]
- Matelski H., Greene R., Huberman M., Zipoli T. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am. J. Clin. Oncol 1985; 8: 128–133, [PUBMED], [INFOTRIEVE], [CSA]
- van Veelen H., Willemse P. H., Tjabbes T., Schwitzer M. J., Sleijfer D. T. Oral high- dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer 1986; 58: 7–13, [PUBMED], [INFOTRIEVE], [CSA]
- Howell A., Dodwell D. J., Anderson H., Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann. Oncol 1992; 8: 611–617, [CSA]
- Hobisch A., Hoffmann J., Lambrinidis L., Eder I. E., Bartsch F, Klocker H., Culig Z. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model. Urol. Int 2000; 65: 73–79, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Small E. J., Carroll P. R. Prostate-specific antigen decline after Casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43: 408–410, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Scher H. I., Kelly W. K. Flutamide. withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol 1993; 11: 1566–1572, [PUBMED], [INFOTRIEVE], [CSA]
- Dawson N. A., McLeod D. G. Dramatic prostate specific antigen decrease in response to discontinuation of megesterol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome. J. Urol 1995; 153: 1946–1947, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brandes L. J., Arron R. J., Bogdanovic R. P., Tong J., Zaborniak C. L.F., Hogg G. R., Warrington R. C., Fang W., LaBella F. S. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992; 52: 3796–3800, [PUBMED], [INFOTRIEVE], [CSA]
- Bendele R. A., Adams E. R., Hoffman W. P., Gries C. L., Morton D. M. Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res 1992; 52: 6931–6935, [PUBMED], [INFOTRIEVE], [CSA]
- Brandes L. J., Cheang M. Letter regarding “Response to antidepressants and cancer: Cause for concern?”. J. Clin. Psychopharmacol 1995; 15: 84–85, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Linkins R. W., Comstock G. W. Depressed mood and development of cancer. Am. J. Epidemiol 1990; 132: 962–972, [PUBMED], [INFOTRIEVE], [CSA]
- Reed S. M., Glick J. N. Fluoxetine and reactivation of the herpes simplex virus. Am. J. Psychiatry 1991; 49: 949–950, [CSA]
- Opelz G., Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514–1561, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brandes L. J. Re: Depression, antidepressant medications, and cancer (letter). Am. J. Epidemiol 1992; 136: 1414–1415, [PUBMED], [INFOTRIEVE], [CSA]
- Dalton S. O., Johansen C., Mellemkjaer L., Sorensen H. T., McLaughlin J. K., Olsen J., Olsen J. H. Antidepressant medications and risk for cancer. Epidemiology 2000; 11: 171–176, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cotterchio M., Krieger N., Darlington G., Steingart A. Antidepressant medication use and breast cancer risk. Am. J. Epidemiol 2000; 151: 951–957, [PUBMED], [INFOTRIEVE], [CSA]
- Sharpe C. R., Collet J. P., Belzile E., Hanley J. A., Boivin J. F. The effect of tricyclic antidepressants on breast cancer risk. Br. J. Cancer 2002; 86: 92–97, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moorman P. G., Grubber J. M., Millikan R. C., Newman B. Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 2003; 14: 307–314, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Steingart A., Cotterchio M., Kreiger N., Sloan M. Antidepressant medication use and breast cancer risk: Case-control study. Int. J. Epidemiol 2003; 32: 961–966, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kelly J. P., Rosenberg L., Palmer J. R., Rao R. S., Strom B. L., Stolley P. D., Zauber A. G., Shapiro S. Risk of breast cancer according to use of antidepressants, phenothiazines and antihistamines. Am. J. Epidemiol 1999; 150: 861–868, [PUBMED], [INFOTRIEVE], [CSA]
- Wang P. S., Walker A. M., Tsuang M. T., Orav E. J., Levin R., Avorn J. Antidepressant use and the risk of breast cancer: A non-association. J. Clin. Epidemiol 2001; 54: 728–734, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Harlow B. L., Cramer D. W., Baron J. A., Titus-Ernstoff L. Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev 1998; 8: 697–702, [CSA]
- Harlow B. L., Cramer D. W. Self-reported use of antidepressants and benzodiazepine tranquilizers and risk of epithelial ovarian cancer: Evidence from two combined case-control studies (Massachusetts, United States). Cancer Causes Control 1995; 6: 130–134, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Coogan P. F., Rosenberg L., Palmer J. R., Strom B. L., Stolley P. D., Zauber A. G., Shapiro S. Risk of ovarian cancer according to use of antidepressants, phenothiazines and benzodiazepines (United States). Cancer Causes Control 2000; 11: 839–845, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dublin S., Rossing M. A., Heckbert S. R., Goff B. A., Weiss N. S. Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally active medications. Cancer Causes Control 2002; 13: 35–45, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Weiss S. R., McFarland B. H., Burkhart G. A., Ho P. T. Cancer recurrences and second primary cancers after use of antihistamines and antidepressants. Clin. Pharmacol. Ther 1998; 63: 594–599, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wallace W. A., Balsitis M., Harrison B. J. Male breast neoplasia in association with selective serotonin re-uptake inhibitor therapy: A report of three cases. Eur. J. Surg. Oncol 2001; 27: 429–431, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Beiderbeck-Noll A. B., Sturkenboom M. C., van der Linden P. D., Herings R. M., Hofman A., Coebergh J. W., Leufkens H. G., Stricker B. H. Verapamil is associated with an increased risk of cancer in the elderly: The Rotterdam study. Eur. J. Cancer 2003; 39: 98–105, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Akechi T., Nakano T., Okamura H. Psychiatric disorders in cancer patients: Descriptive analysis of 1721 psychiatric referrals at two Japanese cancer center hospitals. Jpn. J. Clin. Oncol 2001; 31: 188–194, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dalton S. O., Mellemkjaer L., Olsen J. H., Mortensen P. B., Johansen C. Depression and cancer risk: A register-based study of patients hospitalized with affective disorders, Denmark, 1969–1993. Am. J. Epidemiol 2002; 155: 1088–1095, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brandes L. J., Warrington R. C., Arron R. J., Bogdanovic R. P., Fang W., Queen G., Stein D., Tong J., Zaborniak C. L.F., LaBella F. S. Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: Predictive in vitro correlates. JNCI 1994; 86: 770–775, [PUBMED], [INFOTRIEVE], [CSA]
- LaBella F. S., Brandes L. J. Enhancement of tumor growth by drugs with some common molecular actions. Mol. Carcinogen 1996; 16: 68–76, [CROSSREF], [CSA]
- Kahlson G., Rosengren E. Histamine formation as related to growth and protein synthesis. Biogenic amines as physiological regulators, J. J. Blum. Prentice Hall, Englewood Cliffs, NJ 1970; 223–228
- Nebert D. W. Proposed role of drug-metabolizing enzymes: Regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation and neuroendocrine functions. Mol. Endocrinol 1991; 5: 1203–1214, [PUBMED], [INFOTRIEVE], [CSA]
- Brandes L. J., Queen G. M., LaBella F. S. Displacement of histamine from liver cells and cell components by ligands for cytochromes P450. J. Cell Biochem 2002; 85: 820–824, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brandes L. J., Queen G. M., LaBella F. S. N,N-Diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE), a chemopotentiating and cytoprotective agent in clinical trials: Interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol 2000; 45: 298–304, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ghahramani P., Ellis S. W., Lennard M. S, Ramsay L. E., Tucker G. T. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br. J. Clin. Pharmacol 1997; 43: 137–144, [PUBMED], [INFOTRIEVE], [CSA]
- Margolis J. M., O'Donnell J. P., Mankowski D. C., Ekins S., Obach R S. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab. Dispos 2000; 28: 1187–1191, [PUBMED], [INFOTRIEVE], [CSA]
- Loprinzi C. L., Sloan J. A., Perez E. A., Quella S. K., Stella P. J., Mailliard J. A., Halyard M. Y., Pruthi S., Novotny P. J., Rummans T. A. Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol 2002; 20: 1578–1583, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Stearns V., Beebe K. L., Iyengar M., Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial. J. Am. Med. Assoc. 2003; 289: 2827–2834, [CROSSREF], [CSA]